Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in adults with primary Sjogren's syndrome
jRCT2031210484Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial of nipocalimab in Sjögren's syndrome (SS) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in clinESSDAI score at Week 24. Started Mar 2022; status: completed.
02
Drugs
nipocalimab
03
Conditions
Sjögren's syndrome (SS)
Beyond the preview
Go deeper on jRCT2031210484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210484.